Analysts expect Genomic Health, Inc. (NASDAQ:GHDX) to post $0.38 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Genomic Health’s earnings, with estimates ranging from $0.34 to $0.43. Genomic Health posted earnings of $0.35 per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 8.6%. The firm is expected to announce its next earnings results on Tuesday, November 5th.
On average, analysts expect that Genomic Health will report full year earnings of $1.50 per share for the current fiscal year, with EPS estimates ranging from $1.47 to $1.56. For the next fiscal year, analysts forecast that the firm will report earnings of $1.67 per share, with EPS estimates ranging from $1.47 to $1.91. Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that that provide coverage for Genomic Health.
Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings data on Monday, July 29th. The medical research company reported $0.42 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.35 by $0.07. The firm had revenue of $114.14 million during the quarter, compared to analysts’ expectations of $110.78 million. Genomic Health had a net margin of 11.69% and a return on equity of 19.51%. The company’s revenue for the quarter was up 19.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.23 earnings per share.
In related news, CEO Kimberly J. Popovits sold 25,000 shares of the firm’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $73.85, for a total transaction of $1,846,250.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO G Bradley Cole sold 5,000 shares of the firm’s stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $51.46, for a total transaction of $257,300.00. The disclosure for this sale can be found here. Insiders have sold 290,601 shares of company stock valued at $18,833,446 over the last ninety days. 31.30% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. lifted its position in Genomic Health by 166.0% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 790 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 493 shares during the last quarter. Manchester Capital Management LLC bought a new position in Genomic Health during the first quarter valued at $56,000. Pearl River Capital LLC bought a new position in Genomic Health during the first quarter valued at $70,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Genomic Health by 29.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,923 shares of the medical research company’s stock valued at $112,000 after purchasing an additional 441 shares during the last quarter. Finally, Amalgamated Bank bought a new position in Genomic Health during the fourth quarter valued at $203,000. 95.63% of the stock is owned by institutional investors.
Shares of NASDAQ GHDX traded down $0.30 during midday trading on Wednesday, reaching $74.60. The stock had a trading volume of 31,225 shares, compared to its average volume of 580,696. The business’s 50-day simple moving average is $63.20. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.74 and a quick ratio of 5.74. The company has a market cap of $2.74 billion, a P/E ratio of 71.25 and a beta of 1.06. Genomic Health has a 12-month low of $50.77 and a 12-month high of $92.18.
Genomic Health Company Profile
Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.
See Also: How is a Moving Average Calculated?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.